https://www.cnbc.com/2018/07/24/glaxosmithkline-23andme-team-up-on-genetics-driven-drug-research.html

British drug giant GlaxoSmithKline is investing $300 million in consumer genetics company 23andMe, forging a four-year collaboration to discover medicines using human genetics as a guide.

The partnership establishes GSK as 23andMe’s exclusive collaborator for drug target discovery, the companies said Wednesday. It comes with an option to extend for a fifth year, and funding and proceeds will be split equally.